Vendor, Cambridge, MA
Acousticabio, Inc.
UEI PQD4VEHVHWD6, CAGE 9GAD2
1 award and $295,116 obligated between July 31, 2024 and June 30, 2025, 100% under full and open competition, against 8.0 offers on average where reported. 3 of the awards trace back to a SAM.gov solicitation on this site.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $295,116 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93024C00047Definitive Contract, July 31, 2024, Full and Open Competition After Exclusion of Sources, 8 offersSolicitation | National Institutes of Health NiaidNational Institutes of Health | High-Dose and Sustained Delivery of HIV-1 Broadly Neutralizing Antibodies Via Subcutaneous Injection of Hydrogel-Based Microparticle FormatiNAICS 541715, PSC AN12 | $295,116 |
- Places of performance
- Massachusetts
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 3 across 1 awards